In 2015, WHO included direct-acting antivirals in its Model List of Essential Medicines18 and, in 2016, launched the first global strategy on hepatitis.19 Despite the high burden of hepatitis C among PWID, treatment has occurred at very low levels, which is related to the substantial barriers that exist for PWID in accessing care.20 These include lack of awareness, stigma and discrimination, limited access to hepatitis C testing and treatment and the cost of the medications. International Journal ofDrug Policy, vol. Some examples where action has been taken include Australia, which, since March 2016, has offered universal access to hepatitis C treatment and has identified prisoners and PW1D as priority populations for the expansion of coverage of treatment.